Newsroom

November 2020

• Press release Nov 19, 2020

  New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases

  Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or…
• 
  Story Nov 19, 2020 Discovery

  Predictive analytics could bring medicines to patients faster

  Novartis researchers are using data to accelerate drug development.

• 
  Featured News Nov 19, 2020

  Achieving 100% renewable electricity

• Press release Nov 19, 2020

  Novartis set to achieve 100% renewable electricity in its European operations

  Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas…
• 
  Story Nov 16, 2020 Discovery

  Making Possible: Stepping toward a future with cell and gene therapy

  These stories offer a glimpse into the lives of people touched by a new era of medicine.

• Featured News Nov 16, 2020

  Leading performance in sustainability

  Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.
• Press release Nov 13, 2020

  Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020

  Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis…
• Press release Nov 13, 2020

  New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

   Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female…
• Featured News Nov 11, 2020

  Study suggests there may be two stages of fatal lung disease in COVID-19

• Press release Nov 06, 2020

  Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

  The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical…
• Press release Nov 05, 2020

  Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

  Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx®  at Week 12  vs. placebo, with improvements as early as Week 11  ULTIMATE is the first…
• 
  Story Nov 04, 2020 Discovery

  Need for new heart disease medicines drives wave of potential therapies

  Novartis is investing in a novel type of medicine to reduce the risk of heart disease.